Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74

Philip S. Miller, James Barwell, David R. Poyner, Mark J. Wigglesworth, Stephen L. Garland, Dan Donnelly

Research output: Contribution to journalArticle

Abstract

The receptor for calcitonin gene-related peptide (CGRP) has been the target for the development of novel small molecule antagonists for the treatment of migraine. Two such antagonists, BIBN4096BS and MK-0974, have shown great promise in clinical trials and hence a deeper understanding of the mechanism of their interaction with the receptor is now required. The structure of the CGRP receptor is unusual since it is comprised of a hetero-oligomeric complex between the calcitonin receptor-like receptor (CRL) and an accessory protein (RAMP1). Both the CLR and RAMP1 components have extracellular domains which interact with each other and together form part of the peptide-binding site. It seems likely that the antagonist binding site will also be located on the extracellular domains and indeed Trp-74 of RAMP1 has been shown to form part of the binding site for BIBN4096BS. However, despite a chimeric study demonstrating the role of the N-terminal domain of CLR in antagonist binding, no specific residues have been identified. Here we carry out a mutagenic screen of the extreme N-terminal domain of CLR (residues 23-63) and identify a mutant, Met-42-Ala, which displays 48-fold lower affinity for BIBN4096BS and almost 900-fold lower affinity for MK-0974. In addition, we confirm that the Trp-74-Lys mutation at human RAMP1 reduces BIBN4096BS affinity by over 300-fold and show for the first time a similar effect for MK-0974 affinity. The data suggest that the non-peptide antagonists occupy a binding site close to the interface of the N-terminal domains of CLR and RAMP1.
LanguageEnglish
Pages437-442
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume391
Issue number1
Early online date13 Nov 2009
DOIs
Publication statusPublished - 1 Jan 2010

Fingerprint

Calcitonin Receptor-Like Protein
Calcitonin Gene-Related Peptide Receptors
Tryptophan
Methionine
Binding Sites
Accessories
Migraine Disorders
Clinical Trials
Peptides
Mutation
Molecules
BIBN 4096BS
telcagepant
Proteins

Bibliographical note

Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0)

Keywords

  • azepines
  • calcitonin receptor-like protein
  • humans
  • imidazoles
  • intracellular signaling peptides and proteins
  • membrane proteins
  • methionine
  • piperazines
  • tertiary protein structure
  • quinazolines
  • receptor activity-modifying protein 1
  • receptor activity-modifying proteins
  • calcitonin receptors
  • calcitonin gene-related peptide receptors
  • tryptophan

Cite this

@article{41881ef794f24127bdb55720347206e0,
title = "Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74",
abstract = "The receptor for calcitonin gene-related peptide (CGRP) has been the target for the development of novel small molecule antagonists for the treatment of migraine. Two such antagonists, BIBN4096BS and MK-0974, have shown great promise in clinical trials and hence a deeper understanding of the mechanism of their interaction with the receptor is now required. The structure of the CGRP receptor is unusual since it is comprised of a hetero-oligomeric complex between the calcitonin receptor-like receptor (CRL) and an accessory protein (RAMP1). Both the CLR and RAMP1 components have extracellular domains which interact with each other and together form part of the peptide-binding site. It seems likely that the antagonist binding site will also be located on the extracellular domains and indeed Trp-74 of RAMP1 has been shown to form part of the binding site for BIBN4096BS. However, despite a chimeric study demonstrating the role of the N-terminal domain of CLR in antagonist binding, no specific residues have been identified. Here we carry out a mutagenic screen of the extreme N-terminal domain of CLR (residues 23-63) and identify a mutant, Met-42-Ala, which displays 48-fold lower affinity for BIBN4096BS and almost 900-fold lower affinity for MK-0974. In addition, we confirm that the Trp-74-Lys mutation at human RAMP1 reduces BIBN4096BS affinity by over 300-fold and show for the first time a similar effect for MK-0974 affinity. The data suggest that the non-peptide antagonists occupy a binding site close to the interface of the N-terminal domains of CLR and RAMP1.",
keywords = "azepines, calcitonin receptor-like protein, humans, imidazoles, intracellular signaling peptides and proteins, membrane proteins, methionine, piperazines, tertiary protein structure, quinazolines, receptor activity-modifying protein 1, receptor activity-modifying proteins, calcitonin receptors, calcitonin gene-related peptide receptors, tryptophan",
author = "Miller, {Philip S.} and James Barwell and Poyner, {David R.} and Wigglesworth, {Mark J.} and Garland, {Stephen L.} and Dan Donnelly",
note = "Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0)",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.bbrc.2009.11.076",
language = "English",
volume = "391",
pages = "437--442",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74. / Miller, Philip S.; Barwell, James; Poyner, David R.; Wigglesworth, Mark J.; Garland, Stephen L.; Donnelly, Dan.

In: Biochemical and Biophysical Research Communications, Vol. 391, No. 1, 01.01.2010, p. 437-442.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Non-peptidic antagonists of the CGRP receptor, BIBN4096BS and MK-0974, interact with the calcitonin receptor-like receptor via methionine-42 and RAMP1 via tryptophan-74

AU - Miller, Philip S.

AU - Barwell, James

AU - Poyner, David R.

AU - Wigglesworth, Mark J.

AU - Garland, Stephen L.

AU - Donnelly, Dan

N1 - Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported (CC BY-NC-ND 3.0)

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The receptor for calcitonin gene-related peptide (CGRP) has been the target for the development of novel small molecule antagonists for the treatment of migraine. Two such antagonists, BIBN4096BS and MK-0974, have shown great promise in clinical trials and hence a deeper understanding of the mechanism of their interaction with the receptor is now required. The structure of the CGRP receptor is unusual since it is comprised of a hetero-oligomeric complex between the calcitonin receptor-like receptor (CRL) and an accessory protein (RAMP1). Both the CLR and RAMP1 components have extracellular domains which interact with each other and together form part of the peptide-binding site. It seems likely that the antagonist binding site will also be located on the extracellular domains and indeed Trp-74 of RAMP1 has been shown to form part of the binding site for BIBN4096BS. However, despite a chimeric study demonstrating the role of the N-terminal domain of CLR in antagonist binding, no specific residues have been identified. Here we carry out a mutagenic screen of the extreme N-terminal domain of CLR (residues 23-63) and identify a mutant, Met-42-Ala, which displays 48-fold lower affinity for BIBN4096BS and almost 900-fold lower affinity for MK-0974. In addition, we confirm that the Trp-74-Lys mutation at human RAMP1 reduces BIBN4096BS affinity by over 300-fold and show for the first time a similar effect for MK-0974 affinity. The data suggest that the non-peptide antagonists occupy a binding site close to the interface of the N-terminal domains of CLR and RAMP1.

AB - The receptor for calcitonin gene-related peptide (CGRP) has been the target for the development of novel small molecule antagonists for the treatment of migraine. Two such antagonists, BIBN4096BS and MK-0974, have shown great promise in clinical trials and hence a deeper understanding of the mechanism of their interaction with the receptor is now required. The structure of the CGRP receptor is unusual since it is comprised of a hetero-oligomeric complex between the calcitonin receptor-like receptor (CRL) and an accessory protein (RAMP1). Both the CLR and RAMP1 components have extracellular domains which interact with each other and together form part of the peptide-binding site. It seems likely that the antagonist binding site will also be located on the extracellular domains and indeed Trp-74 of RAMP1 has been shown to form part of the binding site for BIBN4096BS. However, despite a chimeric study demonstrating the role of the N-terminal domain of CLR in antagonist binding, no specific residues have been identified. Here we carry out a mutagenic screen of the extreme N-terminal domain of CLR (residues 23-63) and identify a mutant, Met-42-Ala, which displays 48-fold lower affinity for BIBN4096BS and almost 900-fold lower affinity for MK-0974. In addition, we confirm that the Trp-74-Lys mutation at human RAMP1 reduces BIBN4096BS affinity by over 300-fold and show for the first time a similar effect for MK-0974 affinity. The data suggest that the non-peptide antagonists occupy a binding site close to the interface of the N-terminal domains of CLR and RAMP1.

KW - azepines

KW - calcitonin receptor-like protein

KW - humans

KW - imidazoles

KW - intracellular signaling peptides and proteins

KW - membrane proteins

KW - methionine

KW - piperazines

KW - tertiary protein structure

KW - quinazolines

KW - receptor activity-modifying protein 1

KW - receptor activity-modifying proteins

KW - calcitonin receptors

KW - calcitonin gene-related peptide receptors

KW - tryptophan

UR - http://www.scopus.com/inward/record.url?scp=72949116357&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2009.11.076

DO - 10.1016/j.bbrc.2009.11.076

M3 - Article

VL - 391

SP - 437

EP - 442

JO - Biochemical and Biophysical Research Communications

T2 - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -